Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

286 Views

A6. New drug development (formerly L3)

Poster Session: New Drug Development

(P-1063) SCY-247: A Second-generation IV/Oral Triterpenoid Antifungal with Extensive Tissue Distribution and Pharmacokinetics, and Low Drug-Drug Interaction Potential

Friday, October 18, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Co-Author(s)

Katyna Borroto-Esoda, MS

Preclinical Consultant
SCYNEXIS, Inc.
Jersey City, New Jersey, United States
Nathan P. Wiederhold, PharmD

Professor
University of Texas Health San Antonio
San Antonio, TX, United States

David A. Angulo, MD

Chief Executive Officer
SCYNEXIS, Inc.
Jersey City, NJ, United States